Association between Pretreatment Levels of Serum Vascular Endothelial Growth Factor
(VEGF) and Survival Outcomes in Locally Advanced Cervical Cancer Patients
1483
6. Acknowledgements
The authors gratefully acknowledge the financial support
provided by the medical research fund of Faculty of
Medicine Vajira Hospital, Navamindradhiraj University.
REFERENCES
[1] A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward and
D. Forman, “Global Cancer Statistics,” CA: A Cancer
Journal for Clinicians, Vol. 61, No. 2, 2011, pp. 69-90.
http://dx.doi.org/10.3322/caac.20107
[2] R. Pearcey, M. Brundage, P. Drouin, J. Jeffery, D. Johns-
ton, H. Lukka, et al., “Phase III Trial Comparing Radical
Radiotherapy with and without Cisplatin Chemotherapy
in Patients with Advanced Squamous Cell Cancer of the
Cervix,” Journal of Clinical Oncology, Vol. 20, No. 4,
2002, pp. 966-972.
http://dx.doi.org/10.1200/JCO.20.4.966
[3] Chemoradiotherapy for Cervical Cancer Meta-Analysis
Collaboration, “Reducing Uncertainties about the Effects
of Chemoradiotherapy for Cervical Cancer: A Systematic
Review and Meta-Analysis of Individual Patient Data
from 18 Randomized Trials,” Journal of Clinical Oncol-
ogy, Vol. 26, No. 35, 2008, pp. 5802-5812.
http://dx.doi.org/10.1200/JCO.2008.16.4368
[4] P. Carmeliet and R. K. Jain, “Angiogenesis in Cancer and
Other Diseases,” Nature, Vol. 407, No. 6801, 2000, pp.
249-257. http://dx.doi.org/10.1038/35025220
[5] J. D. Carpini, A. K. Karam and L. Montgomery, “Vascu-
lar Endothelial Growth Factor and Its Relationship to the
Prognosis and Treatment of Breast, Ovarian and Cervical
Cancer,” Angiogenesis, Vol. 13, No. 1, 2010, pp. 43-58.
http://dx.doi.org/10.1007/s10456-010-9163-3
[6] H. S. Moon, S. C. Kim, J. J. Aha and B. H. Woo, “Con-
centration of Vascular Endothelial Growth Factor (VEGF)
and Transforming Growth Factor-β1 (TGF-β1) in the Se-
rum of Patients with Cervical Cancer: Prediction of Re-
sponse,” International Journal of Gynecological Cancer,
Vol. 10, No. 2, 2000, pp. 151-156.
http://dx.doi.org/10.1046/j.1525-1438.2000.00013.x
[7] X. P. Peng, J. D. Li, M. D. Li, X. M. Ye and W. C. Yan,
“Clinical Significance of Vascular Endothelial Growth
Factor in Sera of Patients with Gynecological Malignant
Tumors,” Chinese Journal of Cancer, Vol. 21, 2002, pp.
181-185.
[8] A. Lebrecht, E. Ludwig, A. Huber, M. Klein, C. Schnee-
berger, C. Tempfer, et al., “Serum Vascular Endothelial
Growth Factor and Serum Leptin in Patients with Cervi-
cal Cancer,” Gynecologic Oncology, Vol. 85, No. 1, 2002,
pp. 32-35. http://dx.doi.org/10.1006/gyno.2001.6517
[9] B. Bachtiary, E. Selzer, T. H. Knocke, R. Potter and A.
Obermair, “Serum VEGF Levels in Patients Undergoing
Primary Radiotherapy for Cervical Cancer: Impact on
Progression-Free Survival,” Cancer Letters, Vol. 179, No.
2, 2002, pp. 197-203.
http://dx.doi.org/10.1016/S0304-3835(01)00872-2
[10] S. P. Mathur, R. S. Mathur, E. A. Gray, D. Lane, P. G.
Underwood, M. Kohler, et al., “Serum Vascular Endothe-
lial Growth Factor C (VEGF-C) as a Specific Biomarker
for Advanced Cervical Cancer: Relationship to Insulin-
Like Growth Factor II (IGF-II), IGF Binding Protein 3
(IGF-BP3) and VEGF-B,” Gynecologic Oncology, Vol.
98, No. 3, 2005, pp. 467-483.
http://dx.doi.org/10.1016/j.ygyno.2005.05.003
[11] P. L. M. Zusterzeel, P. N. Span, M. G. K. Dijksterhuis, C.
M. G. Thomas, F. C. G. J. Sweep and L. F. A. G. Mas-
suger, “Serum Vascular Endothelial Growth Factor: A
Prognos- tic Factor in Cervical Cancer,” Journal of Can-
cer Re- search and Clinical Oncology, Vol. 135, No. 2,
2009, pp. 283-290.
http://dx.doi.org/10.1007/s00432-008-0442-y
[12] S. Srivastava, A. Gupta, G. G. Agarwal, S. M. Natu, S.
Uma, M. M. Goel, et al., “Correlation of Serum Vascular
Endothelial Growth Factor with Clinicopathological Pa-
rameters in Cervical Cancer,” Bioscience Trends, Vol. 3,
2009, pp. 144-150.
[13] K. Katanyoo, A. Chantarasri, M. Chongtanakon, K.
Rongsriyam and T. Tantivatana, “Pretreatment Levels of
Serum Vascular Endothelial Growth Factor Do Not Cor-
relate with Outcome in Patients with Locally Advanced
Cervical Cancer,” Asian Pacific Journal of Cancer Pre-
vention, Vol. 12, No. 3, 2011, pp. 1-6.
[14] M. Biedka, R. Makarewicz, A. Marzalek, H. Kardy-
mowicz and A. Goralewska, “Labeling in Microvessel
Density, Lymphatic Vessel, Density and Potential Role
of Proangiogenic and Lymphangiogenic Factors as a Pre-
dictive/Prognostic Factors after Radiotherapy in Patients
with Cervical Cancer,” European Journal of Gynaeco-
logical Oncology, Vol. 33, No. 4, 2012, pp. 399-405.
[15] A. Gadducci, R. Tana, S. Cosio and A. R. Genazzani,
“The Serum Assay of Tumour Markers in the Prognostic
Evaluation, Treatment Monitoring and Follow-Up of Pa-
tients with Cervical Cancer: A Review of the Literature,”
Critical Reviews in Oncology/Hematology, Vol. 66, No. 4,
2008, pp. 10-20.
http://dx.doi.org/10.1016/j.critrevonc.2007.09.002
[16] F. Forni, G. Ferrandina, F. Deodato, G. Macchia, A. G.
Morganti, D. Smaniotto, et al., “Squamous Cell Carci-
noma Antigen in Follow-Up of Cervical Cancer Treated
with Radiotherapy: Evaluation of Cost-Effectiveness,”
International Journal of Radiation Oncology, Biology,
Physics, Vol. 69, No. 4, 2007, pp. 1145-1149.
http://dx.doi.org/10.1016/j.ijrobp.2007.04.055
[17] R. A. Burger, “Role of Vascular Endothelial Growth Fac-
tor Inhibitors in the Treatment of Gynecologic Malig-
nancies,” Journal of Gynecologic Oncology, Vol. 21, No.
1, 2010, pp. 3-11.
http://dx.doi.org/10.3802/jgo.2010.21.1.3
[18] L. P. Garrison, D. Lubeck, D. Lalla, V. Paton, A. Dueck
and E. A. Perez, “Cost-Effectiveness Analysis of Tras-
tuzumab in the Adjuvant Setting for Treatment of HER2-
Positive Breast Cancer,” Cancer, Vol. 110, No. 3, 2007,
pp. 489-498. http://dx.doi.org/10.1002/cncr.22806
Open Access JCT